跳至主要内容
临床试验/CTRI/2022/01/039541
CTRI/2022/01/039541招募中未知

TAF (Tenofovir Alafenamide) for preventing progression of liver disease in non-cirrhotic chronic HBV infection with normal ALT and low viral load ââ?¬â?? a randomized controlled trial.

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. HBsAg+
  • 2.Persistent normal ALT 3-6m apart ( <30 IU/ml in male and <20 IU/ml in female)
  • 3.HBV DNA < 2000 IU/ml
  • 4.LSM <8 Kpa

排除标准

  • 1.Prior NUC/IFN exposure.
  • 2.Renal dysfunction (Serum Creatinine >1.5
  • 3.Known liver cirrhosis/ esophageal varices.
  • 4.Any clinical decompensation (CD).
  • 5.Pre-existing hepatocellular carcinoma.
  • 6.Pregnancy
  • 7.Healthcare workers (HCW).
  • 8.Post transplant, patients with advance
  • malignancy or on chemotherapy.
  • 9.Co-infections ââ?¬â?? Hepatitis C, Hepatitis D,
  • Human immunodeficiency virus.

研究者

相似试验